SEC Form 4 · accession 0000899243-15-005951

Clovis Oncology, Inc. · CLVS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Executive VP and CFO

Period of report

Oct 1, 2015

Accepted (ET)

Oct 2, 2015 · 4:15 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001466301

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F4	Oct 1, 2015	S	900	$89.40	D	140,683	D
Common Stock^F2,F4	Oct 1, 2015	S	1,580	$90.28	D	139,103	D
Common Stock^F3,F4	Oct 1, 2015	S	420	$91.30	D	138,683	D
Common Stock^F4	Oct 1, 2015	S	100	$92.09	D	138,583	D

No Table II lines on this filing.

F1This transaction was executed in multiple trades at prices ranging from $88.91 to $89.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2This transaction was executed in multiple trades at prices ranging from $89.94 to $90.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $91.00 to $91.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2014.